| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T0 |
44-48 |
CHEBI_50906 |
denotes |
role |
| T1 |
56-63 |
DOID_4 |
denotes |
disease |
| T2 |
64-72 |
HP_0012824 |
denotes |
severity |
| T3 |
90-98 |
DOID_0080600 |
denotes |
COVID-19 |
| T18 |
90-98 |
HP_0033141 |
denotes |
COVID-19 |
| T16 |
106-133 |
CHEBI_67079 |
denotes |
anti-inflammatory therapies |
| T17 |
186-219 |
GO_0002526 |
denotes |
uncontrolled inflammatory cascade |
| T4 |
267-278 |
CHEBI_64360 |
denotes |
tocilizumab |
| T5 |
404-412 |
DOID_0080600 |
denotes |
COVID-19 |
| T19 |
404-412 |
HP_0033141 |
denotes |
COVID-19 |
| T6 |
503-514 |
CHEBI_64360 |
denotes |
tocilizumab |
| T7 |
584-592 |
HP_0012826 |
denotes |
moderate |
| T8 |
596-602 |
HP_0012828 |
denotes |
severe |
| T9 |
603-611 |
DOID_0080600 |
denotes |
COVID-19 |
| T20 |
603-611 |
HP_0033141 |
denotes |
COVID-19 |
| T10 |
736-744 |
CHEBI_82594 |
denotes |
ferritin |
| T11 |
761-768 |
CHEBI_24996 |
denotes |
lactate |
| T12 |
930-938 |
DOID_0080600 |
denotes |
COVID-19 |
| T21 |
930-938 |
HP_0033141 |
denotes |
COVID-19 |
| T13 |
1163-1170 |
HP_0030645 |
denotes |
central |
| T14 |
1562-1583 |
GO_0006954 |
denotes |
inflammatory response |
| T15 |
1587-1595 |
DOID_0080600 |
denotes |
COVID-19 |
| T22 |
1587-1595 |
HP_0033141 |
denotes |
COVID-19 |
| R0 |
T14 |
T2 |
no_relation |
inflammatory response,severity |
| R1 |
T14 |
T7 |
no_relation |
inflammatory response,moderate |
| R10 |
T3 |
T6 |
effect |
COVID-19,tocilizumab |
| R11 |
T3 |
T10 |
effect |
COVID-19,ferritin |
| R12 |
T3 |
T11 |
effect |
COVID-19,lactate |
| R13 |
T5 |
T0 |
no_relation |
COVID-19,role |
| R14 |
T5 |
T4 |
effect |
COVID-19,tocilizumab |
| R15 |
T5 |
T6 |
effect |
COVID-19,tocilizumab |
| R16 |
T5 |
T10 |
effect |
COVID-19,ferritin |
| R17 |
T5 |
T11 |
effect |
COVID-19,lactate |
| R18 |
T9 |
T0 |
no_relation |
COVID-19,role |
| R19 |
T9 |
T4 |
effect |
COVID-19,tocilizumab |
| R2 |
T14 |
T8 |
no_relation |
inflammatory response,severe |
| R20 |
T9 |
T6 |
effect |
COVID-19,tocilizumab |
| R21 |
T9 |
T10 |
effect |
COVID-19,ferritin |
| R22 |
T9 |
T11 |
effect |
COVID-19,lactate |
| R23 |
T12 |
T0 |
no_relation |
COVID-19,role |
| R24 |
T12 |
T4 |
effect |
COVID-19,tocilizumab |
| R25 |
T12 |
T6 |
no_relation |
COVID-19,tocilizumab |
| R26 |
T12 |
T10 |
no_relation |
COVID-19,ferritin |
| R27 |
T12 |
T11 |
no_relation |
COVID-19,lactate |
| R28 |
T15 |
T0 |
no_relation |
COVID-19,role |
| R29 |
T15 |
T4 |
effect |
COVID-19,tocilizumab |
| R30 |
T15 |
T6 |
no_relation |
COVID-19,tocilizumab |
| R31 |
T15 |
T10 |
no_relation |
COVID-19,ferritin |
| R32 |
T15 |
T11 |
no_relation |
COVID-19,lactate |
| R33 |
T16 |
T17 |
effect |
anti-inflammatory therapies,uncontrolled inflammatory cascade |
| R34 |
T8 |
T20 |
effect |
severe,COVID-19 |
| R35 |
T7 |
T20 |
effect |
moderate,COVID-19 |
| R36 |
T7 |
T9 |
effect |
moderate,COVID-19 |
| R37 |
T8 |
T9 |
effect |
severe,COVID-19 |
| R38 |
T22 |
T14 |
effect |
COVID-19,inflammatory response |
| R39 |
T15 |
T14 |
effect |
COVID-19,inflammatory response |
| R4 |
T1 |
T4 |
effect |
disease,tocilizumab |
| R5 |
T1 |
T6 |
effect |
disease,tocilizumab |
| R6 |
T1 |
T10 |
effect |
disease,ferritin |
| R7 |
T1 |
T11 |
effect |
disease,lactate |
| R8 |
T3 |
T0 |
no_relation |
COVID-19,role |
| R9 |
T3 |
T4 |
effect |
COVID-19,tocilizumab |
